What is Ovarian Cancer?
Ovarian cancer is a rare cancer that affects the ovaries. It is the most common form of female reproductive cancer. In its early stages, it is often found to be advanced and life-threatening.
Ovarian cancer is one of the most serious forms of gynecological cancer. It begins when cells from the ovaries begin to grow abnormally and start multiplying uncontrollably. As these cells continue to multiply, they invade surrounding tissues and destroy them. This eventually leads to the formation of tumors that can cause severe symptoms such as bleeding, abdominal pain, constipation or diarrhea, nausea, vomiting, bloating, and weight gain.
Why is Ovarian Cancer being studied in clinical trials?
Ovarian cancer is a deadly disease that has a high mortality rate, especially when it has metastasized to other surrounding organs. Currently, there are no effective treatments for ovarian cancer, and most patients die within one year of diagnosis. The discovery of new therapies for ovarian cancer would be a major breakthrough in the treatment of this disease.
To date, no studies have been conducted to evaluate the effectiveness of new therapies for this type of cancer. Clinical trials are used to test new treatments or therapies on human volunteers with diseases or conditions that may benefit from them. In these studies, participants receive an experimental treatment under supervision by a physician and researchers in order to evaluate its effectiveness.
How Do Ovarian Cancer clinical trials work?
The first step in conducting a clinical trial is determining whether patients would benefit from the treatment being tested or not. This requires gathering information about how well other treatments are working for similar conditions, as well as what side effects those treatments have caused. If a study shows that a drug will help reduce symptoms of ovarian cancer in some patients who have already been diagnosed with it, then testing it on patients who haven't yet been diagnosed is unnecessary. It usually devolves into three phases: Phase I, II, and III.
Phases I and II trials are smaller studies focused on determining whether a drug works. These studies usually involve about 40-60 people at a time, but they can be expanded to as many as 150 people if necessary. In phase I research, you'll be assigned to take part in four different groups: treatment group (which takes the drug); placebo control group; active control group; and observation group (which doesn't take part in any treatment). In phase II research, you'll be assigned to take part in two different groups: the treatment group (which takes the drug); the placebo control group; and the active control group (which doesn't take part in any treatment).
What are Some Key Breakthrough Clinical Trials Involving Ovarian Cancer?
There are some promising new developments that may help women with ovarian cancer avoid the most common forms of this disease. Here are some key breakthrough clinical trials involving Ovarian Cancer:
2021: A phase-three trial of a drug called Entresto (evolocumab) was conducted in patients with early-stage ovarian cancer who did not have a life-threatening illness and were not eligible for chemotherapy or other targeted therapies. Those who received the drug lived an average of 4.5 months longer than those who didn't receive it—a statistically significant difference that was enough to earn approval from the Food and Drug Administration (FDA).
2013: Another trial tested Sutent (sunitinib) in patients with advanced ovarian cancer. The study found that patients taking both drugs had a significantly longer survival rate than those given just one drug, which suggests that they could potentially gain more benefit from the combination therapy than they would from either treatment alone.
Who are the key opinion leaders on Ovarian Cancer clinical trial research?
There are many key opinion leaders on ovarian cancer clinical trial research, which are almost concentrated on the main members of the Ovarian Cancer Research Alliance (OCRA):
Dr. Ronald Alvarez is the chairman of the Department of Obstetrics and Gynecology at Vanderbilt University Medical Center (Nashville, Tennessee). He has contributed to hundreds and hundreds of articles and research regarding ovarian cancer research.
Dr. Molly Brewer is a professor and head of the OB-Gyne Department in the University of CT Health Center. She worked with other experts in the field in developing technology to explore the ovary for signs of cancer.
Top Hospitals for Ovarian Cancer Clinical Trials
After looking at the top hospitals in the world that conducts ovarian cancer clinical trials, M.D. Anderson Cancer Center in Houston, Texas, has been found to as the leader in such research. This hospital is one of only about 20 National Cancer Institute-designated comprehensive cancer centers in the United States, which means it has been recognized by the federal government for its exceptional programs and expertise in treating cancer. As a leading world-class cancer center, M.D. Anderson has a long list of patients who have suffered from the disease, but after undergoing treatment at the hospital, their chances of survival increased significantly because of their care at this institution. Check out more top hospitals conducting ovarian cancer clinical trials below.
Top Cities for Ovarian Cancer Clinical Trials
The city of Boston, Massachusetts, is listed to be the most popular city for ovarian cancer clinical trials, with a record of 77 total active cases. The City of Boston is located on a peninsula in the northeastern section of Massachusetts and is the capital of the state. Boston has a population of 691,000 people, and it is known as America's "Hub City." Other cities listed as top cities for ovarian cancer clinical trials can be seen below.
Top Treatments for Ovarian Cancer Clinical Trials
According to Power’s database, Paclitaxel is the top-rated treatment technique that is used for ovarian cancer clinical trials, with a total of 10 active cases.
Paclitaxel is an effective treatment for ovarian cancer because it works by blocking the growth of tumor cells. It does this by blocking a protein called MET, which is necessary for the development of tumors. The drug also activates a patient's immune system to destroy tumor cells and prevent them from dividing. Paclitaxel is approved for use in treating ovarian cancer after surgery, but can also be used to treat disease progression when given before or after surgery. The drug is taken orally once every three weeks, and it's given intravenously two times per week when given before surgery or at other times as directed by a doctor.
More treatments for ovarian cancer clinical trials are found below.
How many Vitiligo clinical trials are open to youth and/or seniors?
Power’s list shows that those 18 and above are the most numerous active clinical trials available for ovarian cancer. This is because young women are at the peak of their reproductive years, which is a period of increased risk for developing this type of cancer. Ovarian cancer is also more common in women who have gone through menopause, and those who have had children. This is because ovarian cancer tends to be more aggressive in older women, and it's possible that the hormonal changes experienced with menopause and childbirth may increase its incidence rate. Occurrences regarding other age groups can be explored below.